Suchergebnisse - "F0P408N6V4"

PubPharm (3.679)

11

Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma

enthalten in: Journal for immunotherapy of cancer | 2024

von Coffey, D. | Osman, K. | Aleman, A. | +10

12

Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML

enthalten in: Blood | 2024

von Bourgeois, W. | Cutler, J. | Aubrey, B. | +22

CommentIn: Blood. 2024 Apr 11;143(15):1438-1439. - PMID 38602697

13

The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma : Considerations on behalf of the Chronic Malignancies Working Party of the EBMT

enthalten in: British journal of haematology | 2024

von Hwang, A. | Hayden, P. | Pawlyn, C. | +2

14

Megalosplenia as an initial manifestation of multiple myeloma with a novel CYLD gene mutation : A case report and literature review

enthalten in: Medicine | 2024

von Zhang, J. | Zhang, R.

15

Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain

enthalten in: European journal of haematology | 2024

von Lehne, M. | Kortüm, K. | Ramasamy, K. | +10

16

INSURE : a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice

enthalten in: Future oncology (London, England) | 2024

von Leleu, X. | Lee, H. | Zonder, J. | +10

17

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation

enthalten in: Haematologica | 2024

von Epstein-Peterson, Z. | Drill, E. | Aypar, U. | +21

18

Emergence of TP53 mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine

enthalten in: Haematologica | 2024

von Gangat, N. | Bellam, N. | Reichard, K. | +1

19

A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma : The northern Italy experience

enthalten in: Cancer medicine | 2024

von Furlan, A. | Cea, M. | Pavan, L. | +25

20

Immune profiles to predict bortezomib-based treatment response for multiple myeloma patients

enthalten in: International immunopharmacology | 2024

von Liu, Z. | Shen, H. | Han, M. | +5